Induction of β-cell rest in type 1 diabetes: Studies on the effects of octreotide and diazoxide

Diabetes Care

Volumn 21, Issue 3, 1998, Pages 427-430

  Björk, Elisabeth ^a   Berne, Christian ^a   Karlsson, F Anders ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIAZOXIDE; INSULIN; OCTREOTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PROTEIN SECRETION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; C-PEPTIDE; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 1; DIAZOXIDE; FEMALE; FOOD; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HORMONES; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; OCTREOTIDE; POSTPRANDIAL PERIOD;

EID: 2642639645     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.3.427     Document Type: Article

References (36)

1. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
2. Jansson L, Eizirik DL, Pipeleers DG, Borg LAH, Hellerström C, Andersson A: Impairment of glucose-induced insulin secretion in human pancreatic islets transplanted to diabetic nude mice. J Clin Invest 96:721-726, 1995
3. r islet cell autoantigen expression. Diabetes 38:1326-1328, 1989
4. Hagopian WA, Karlsen AE, Petersen JS, Teague J, Gervassi A, Jiang J, Fujimoto W, Lernmark A: Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina. Endocrinology 132:2674-2681, 1993
5. 65 in human pancreatic islets. J Clin Endocrinol Metab 75:1574-1576, 1992
6. Björk E, Kämpe O, Andersson A, Karlsson FA: Expression of the 64 kDa/glutamic acid decarboxylase rat islet cell autoantigen is influenced by the rate of insulin secretion. Diabetologia 32:490-493, 1992
7. Björk E, Kämpe O, Grawé J, Hallberg A, Norheim I, Karlsson FA: Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity. Autoimmunity 16:181-188, 1993
8. Björk E, Berne C, Kämpe O, Wibell L, Oskarsson P, Karlsson FA: Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427-1430, 1996
9. Karlsson FA, Björk E: Beta-cell rest: a strategy for the prevention of autoimmune diabetes. Autoimmunity 26:117-122, 1997
10. Lamberts SWJ, Van Der Lely A-J, De Herder WW, Hofland LJ: Octreotide. N Engl J Med 334:246-254, 1996
11. Acromegaly Therapy Consensus Development Panel: Benefits versus risks of medical therapy for acromegaly. Am J Med 97:468-473, 1994
12. Plewe G, Beyer J, Krause U, Neufeld M, Del Pozo E: Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS201-995 in acromegaly. Lancet ii:782-784, 1984
13. Gama R, Marks V, Wright J, Teale JD: Octreotide exacerbated fasting hypoglycemia in a patient with a proinsulinoma: the glucostatic importance of pancreatic glucagon. Clin Endocrinol 43:117-120, 1995
14. Möller N, Bagger JP, Schmitz O, Jörgensen, JO, Ovesen P, Möller J, Alberti KG, Orskov H: Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm. J Clin Endocrinol Metab 80:1789-1793, 1995
15. Petit P, Loubatières-Mariani MM: Potassium channels of the insulin-secreting B cell. Fundam Clin Pharmacol 6:123-134, 1992
16. Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA: Diazoxide in the management of patients with insulinoma. World J Surg 10:586-592, 1986
17. Grant DB, Dunger DB, Burns EC: Long-term treatment with diazoxide in childhood hyperinsulinism. Acta Endocrinol 113:340-345, 1986
18. + channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci 47:1693-1705, 1990
19. Catterall W, Epstein PN: Ion channels. Diabetoiogia 35 (Suppl. 2):S23-S33, 1992
20. Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA: Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 123:637-643, 1993
21. Permutt MA, Nestorowicz A, Glaser B: Familial hyperinsulinism: an inherited disorder of spontaneous hypoglycemia in neonates and infants. Diabetes Rev 4:347-355, 1996
22. Thomas P, Ye Y, Lightner E: Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 5:1809-1812, 1996
23. Dunne MJ, Kane C, Shepherd RM, Sanchez JA, James RF, Johnson PR, Aynsley-Green A, Lu S, Clement JP, Lindley KJ, Seino S, Aguilar-Bryan L: Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N Engl J Med 336:703-706, 1997
24. Verchere CB, Kwok YN, Brown JC: Inhibitory actions of a somatostatin analog SMS 201-995 on endocrine secretion from the isolated perfused stomach and pancreas of the rat. Pharmacology 46:50-60, 1993
25. Davies RR, Miller M, Turner SJ, Goodship TH, Cook DB, Watson M, McGill A, Orskov H, Alberti KG, Johnston DG: Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol (Oxf.) 24:665-674, 1986
26. Spinas GA, Bock A, Keller U: Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care 8:429-435, 1985
27. Candrina R, Guistina G: Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients. J Endocrinol Invest 11:501-507, 1988
28. Serrano Rios M, Navascues I, Saban J, Ordonez A, Sevilla F, Del Pozo E: Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J Clin Endocrinol Metab 63:1071-1074, 1986
29. Ezzat S, Melmed S: Endocrine applications of the somatostatin analogue octreotide (Sandostatin). Metabolism 41:34-38, 1992
30. Camilleri M: Effects of somatostatin analogues on human gastrointestinal motility Digestion 57 (Suppl. 1):90-92, 1996
31. Bergman RN, Ader M, Finegood DT, Pacini G: Extrapancreatic effect of somatostatin infusion to increase glucose clearance. Am J Physiol 47:E370-E379, 1984
32. Wu MS, Ho LT, Chen JJ, Reaven GM: Somatostatin potentiation of insulin-induced glucose uptake in normal individuals. Am J Physiol 251:E674-E679, 1984
33. Stevenson RW, Steiner KE, Hendrick GK, Cherrington AD: Effect of somatostatin on glucose homeostasis in conscious long-fasted dogs. Am J Physiol 253:E435-E442, 1987
34. Hendrick GK, Frizzell RT, Cherrington AD: Effect of somatostatin on nonesterified fatty acid levels modifies glucose homeostasis during fasting. Am J Physiol 253:E443-E452, 1987
35. Meneilly GS, Elahi D, Minaker KL, Rowe JW: Somatostatin enhances insulin-mediated glucose disposal in the elderly. J Clin Endocrinol Metab 67:407-410, 1988
36. Alemzadeh R, Slonim AE, Zdanowicz MM, Maturo J: Modification of insulin resistance by diazoxide in obese Zucker rats. Endocrinology 133:705-712, 1993